BR112022026356A2 - Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6 - Google Patents

Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6

Info

Publication number
BR112022026356A2
BR112022026356A2 BR112022026356A BR112022026356A BR112022026356A2 BR 112022026356 A2 BR112022026356 A2 BR 112022026356A2 BR 112022026356 A BR112022026356 A BR 112022026356A BR 112022026356 A BR112022026356 A BR 112022026356A BR 112022026356 A2 BR112022026356 A2 BR 112022026356A2
Authority
BR
Brazil
Prior art keywords
activity
diseases associated
interleukin
aberrant
treat diseases
Prior art date
Application number
BR112022026356A
Other languages
English (en)
Inventor
Evgenievich Nebolsin Vladimir
Original Assignee
Valenta Intellekt Ltd
Evgenievich Nebolsin Vladimir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/ru
Application filed by Valenta Intellekt Ltd, Evgenievich Nebolsin Vladimir filed Critical Valenta Intellekt Ltd
Publication of BR112022026356A2 publication Critical patent/BR112022026356A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

USO DE UM DERIVADO DE GLUTARIMIDA PARA TRATAR DOENÇAS ASSOCIADAS À ATIVIDADE ABERRANTE DA INTERLEUCINA-6. A presente invenção refere-se à medicina e diz respeito ao tratamento de doenças associadas à atividade aberrante da Interleucina-6 e ao desenvolvimento da síndrome de liberação de citocinas (tempestade de citocinas), preferencialmente o tratamento de COVID19, bem como de outras doenças complicadas pela atividade aberrante da Interleucina-6 e o desenvolvimento da síndrome de liberação de citocinas, utilizando o composto 1-(2-(1-metil-1H-imidazol-4-il)etil)piperidina-2,6-diona (fórmula I). A invenção refere-se à criação de um fármaco eficaz para o tratamento de doenças associadas ao desenvolvimento da síndrome de liberação de citocinas.
BR112022026356A 2020-06-26 2021-06-18 Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6 BR112022026356A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (ru) 2020-06-26 Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
PCT/RU2021/050170 WO2021262040A1 (ru) 2020-06-26 2021-06-18 Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6

Publications (1)

Publication Number Publication Date
BR112022026356A2 true BR112022026356A2 (pt) 2023-01-17

Family

ID=79281595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026356A BR112022026356A2 (pt) 2020-06-26 2021-06-18 Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6

Country Status (6)

Country Link
CN (1) CN115803026A (pt)
BR (1) BR112022026356A2 (pt)
CL (1) CL2022003725A1 (pt)
CO (1) CO2023000604A2 (pt)
MA (1) MA58653B1 (pt)
WO (1) WO2021262040A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
CN102432544B (zh) * 2011-11-17 2014-05-21 天津医科大学 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用
CN110229140B (zh) * 2013-04-12 2022-06-10 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
US11439631B2 (en) * 2017-09-07 2022-09-13 “ChemImmune Therapeutics” Limited Liability Company Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
CA3175420A1 (en) * 2020-04-13 2021-10-21 Mark R. Bray Methods for treating cytokine release syndrome
WO2021219078A1 (zh) * 2020-04-30 2021-11-04 上海科技大学 基于杂环和戊二酰亚胺骨架的化合物及其应用

Also Published As

Publication number Publication date
MA58653A1 (fr) 2023-07-31
CL2022003725A1 (es) 2023-05-19
RU2020121363A3 (pt) 2021-12-27
MA58653B1 (fr) 2024-02-29
WO2021262040A1 (ru) 2021-12-30
RU2020121363A (ru) 2021-12-27
CN115803026A (zh) 2023-03-14
CO2023000604A2 (es) 2023-01-26

Similar Documents

Publication Publication Date Title
CY1121107T1 (el) Φαρμακοτεχνικες μορφες δισκιων αμεσης απελευθερωσης
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX2020007092A (es) Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos.
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
ECSP066302A (es) Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones
AR062841A1 (es) Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201001857A1 (ru) Фармацевтическая лекарственная форма для немедленного высвобождения производного индолинона
BR112022026356A2 (pt) Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6
BRPI0519040A2 (pt) tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
BR112021011325A2 (pt) Derivados de rapamicina
CY1106225T1 (el) Διαδικασια για την παρασκευη της 2-μεθυλ πιπepαζινης
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
CY1112718T1 (el) Ν- (2-υδροξυαιθυλ) -ν-μεθυλ-4- (κινολιν-8-υλ (1- (θειαζολ-4-υλμεθυλ) πιπεριδιν- 4 -υλιδενο) μεθυλ) βενζαμιδιο, η μεθοδος παρασκευης του καθως και η χρηση του για τη θεραπευτικη αγωγη πονου, αγχους και καταθλιψης
BR112023001924A2 (pt) Derivados de benzimidazol, método de preparo para os mesmos e uso médico dos mesmos
AR059838A1 (es) Formulaciones para dosis estabilizantes de estatina